Abstract 5477: Cell avidity - the next-gen cell binding to understand the mechanism of action through cell-cell and cell-protein interaction

Abstract Traditional assays such as affinity measurements, cytokine secretion, and cytotoxicity provide informative insights but are insufficient for comprehensively characterizing and selecting the most effective cell therapy candidates. The complexity of cell-cell interactions that drive functional outcomes remains inadequately understood. Cell avidity, defined as the aggregate strength of interactions between effector and target cells, serves as a novel pivotal metric for uncovering the mechanism of action behind therapeutic candidates. The z-Movi Cell Avidity Analyzer, part of our versatile Cell Avidity platform, leverages the integration of fluorescence microscopy with precise acoustic force application to measure cell binding under physiologically relevant conditions. This approach allows for a detailed analysis of binding profiles, encompassing cell surface receptors and ligands, cell phenotype, cell status, and more to elucidate potency, safety, sensitivity, and binding kinetics essential for robust therapeutic evaluation. Our platform is designed to support the characterization and screening of a wide array of therapeutic modalities, including molecular binders like antibodies and small molecules, as well as cell-based therapies. By providing extensive insights into the mechanism of action and functional performance, Cell Avidity enables the development of next-generation therapeutics with enhanced safety and efficacy profiles. Citation Format: Zhou Zhong, Keith Bailey, Justin Moser, Bella Perez, Brian Kierce, Michael Savage. Cell avidity - the next-gen cell binding to understand the mechanism of action through cell-cell and cell-protein interaction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5477.